MIT and MGH researchers introduced "ScribblePrompt," a novel AI framework designed to streamline medical image segmentation.
According to a new study published in The Lancet Digital Health, women around the world could benefit from improved treatment, thanks to new AI technology that allows for better detection of damaged cells and more precise prediction of the risk of developing breast cancer.
The SPACE platform leverages spatial biology and VR technology to create detailed tumor maps, enabling researchers to study tumors in 3D and predict treatment responses.
The International Myeloma Foundation (IMF) is proud to announce the launching of Myelo—the first AI-powered responsive chatbot designed to act as the IMF’s virtual assistant for patients, care partners, and healthcare professionals.
EDAP TMS SA, the global leader in robotic energy-based therapies, and Avenda Health (“Avenda”), a leading AI healthcare company, today announced a collaboration agreement for the purpose of offering personalized prostate cancer care, utilizing Avenda’s groundbreaking AI technology, Unfold AI, to launch the world’s first AI-assisted Focal One robotic high-intensity focused ultrasound (HIFU) procedures.
VisualDx, an award-winning, diagnostic clinical decision support system was developed to provide clinical support and to enhance the accuracy and efficiency of the dermatologic diagnostic process.
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies and Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, announced today a research collaboration aimed at leveraging each company’s expertise to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer.
A survey conducted by Uppsala University in Sweden and published in BMJ Health and Care Informatics found that many UK general practitioners (GPs) are incorporating generative AI tools like ChatGPT into their clinical workflows.
Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces positive one-year data from the ongoing phase 2 trial with its lead asset EVX-01, an AI-designed personalized cancer vaccine.
The ARViS robotic system automates virus injections into the brain with remarkable precision and minimal bleeding, advancing neuroscience research by enabling consistent and reliable studies of brain function and neurological disorders in rodents and non-human primates
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.